Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
William Timothy Garvey, Rachel Louise Batterham, Meena Bhatta, Silvio Buscemi, Louise N. Christensen, Juan P. Frías, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A. Wadden, Sean Wharton, the STEP 5 Study Group
Abstract
Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit). Most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m–2 and weight of 106.0 (22.0) kg. The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001). More participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77.1% versus 34.4%; P < 0.0001). Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%). In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. NCT03693430
Abstract of "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial" by William Timothy Garvey, Rachel Louise Batterham, Meena Bhatta et al., https://doi.org/10.1038/s41591-022-02026-4, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.
Record
- Archive ID
- doi:10.1038/s41591-022-02026-4
- Published
- Oct 1, 2022
- Venue
- Nature Medicine
- DOI
- 10.1038/s41591-022-02026-4
- PubMed
- 36216945
- PMC
- PMC9556320
- Categories
- Pharmacology and Obesity Treatment
- License
- cc-by
- Provenance
- openalex+europepmc